Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
NCT ID: NCT00263874
Last Updated: 2007-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
324 participants
INTERVENTIONAL
2005-11-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UK-500,001
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smoking history of at least 10 pack-years
Exclusion Criteria
* Use of any maintenance therapy except short acting bronchodilators
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Vicente López, Buenos Aires, Argentina
Pfizer Investigational Site
Rosario, Santa Fé, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Camperdown, New South Wales, Australia
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Red Deer, Alberta, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Kingston, Ontario, Canada
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Providencia, Santiago Metropolitan, Chile
Pfizer Investigational Site
ValparaÃ-so, ValparaÃ-so, Chile
Pfizer Investigational Site
Zagreb, , Croatia
Pfizer Investigational Site
Olomouc, , Czechia
Pfizer Investigational Site
Ostrava-Poruba, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Tábor, , Czechia
Pfizer Investigational Site
Debrecen, , Hungary
Pfizer Investigational Site
Törökbálint, , Hungary
Pfizer Investigational Site
Veszprém, , Hungary
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vestbo J, Tan L, Atkinson G, Ward J; UK-500,001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J. 2009 May;33(5):1039-44. doi: 10.1183/09031936.00068908. Epub 2009 Feb 12.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5641009
Identifier Type: -
Identifier Source: org_study_id